MedTech 100 roundup: Another peak for the industry

Medtech has been on the rise in 2021 and the past week saw that trend continue, as the industry hit yet another all-time best mark.

MassDevice‘s MedTech 100 index reached 107.4 points on Jan. 20, topping the all-time best of 106.81 points set on Jan. 8. That mark represents a 16% jump from the pre-pandemic high of 92.32 set on Feb. 19, 2020, and a 72.9% overall leap from the lowest point of 62.13 set on March 23, 2020.

Here are some of the best-performing medtech stocks from 2020.

The high point could not be sustained, but the industry stayed strong, finishing at 106.4 to end the week on Jan. 22. Medtech’s finish to last week was enough to top the previous seven days, coming in 0.6% ahead of the 105.8-point mark set on Jan. 15.

While medtech saw slight growth from the previous week, one of the overall markets saw a larger jump, with the S&P 500 Index rising 1.9%. The Dow Jones Industrial Average fared identically to medtech, rising 0.6%.

Read more
  • 0

ReShape Lifesciences slides on Q2 losses

ReShape Lifesciences (OTC:RSLS) shares took a hit yesterday on second-quarter results that highlighted big losses.

The San Clemente, Calif.-based obesity and metabolic disease treatment developer posted losses of -$3.6 million, or -52¢ per share, on sales of $1.7 million for the three months ended June 30, 2020, for a 77% bottom-line gain on a sales decline of -61.8%.

“The ability for physicians to directly interact with their patients virtually has become increasingly important as obesity is the most-prevalent and severe underlying condition for COVID-19,” ReShape president & CEO Bart Bandy said in a news release. “ReShapeCare is a result of our company’s commitment and focus to drive revenue and shareholder value by expanding our differentiated offerings through new program development.

“While second-quarter revenue was materially impacted by COVID-19, trends in the last month suggest moderate stabilization in segments of …

Read more
  • 0